“A combo of Bristol Myers’ LAG-3 inhibitor relatlimab and PD-1 blocker Opdivo posted a progression-free survival of 10.12 months in patients with metastatic or unresectable melanoma compared with 4.63 months for patients on Opdivo alone, according to data from the Phase II/III RELATIVITY-047 study set to be presented at ASCO in June.”
“On top of adding a novel molecule into the fold, an approval would crack open a whole new world of combo potential for Opdivo, Bristol Myers’ third-bestselling drug and a clear No. 2 in terms of PD-1 sales behind Merck’s behemoth Keytruda. Opdivo cleared $1.72 billion in sales in Q1.”
https://endpts.com/asco21-bristol-m...udy-for-lag-3-pathway-setting-up-a-us-filing/
Industry news, page-2
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.005(0.34%) |
Mkt cap ! $242.5M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.43 | $62.91K | 43.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 591 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
-0.005 ( 0.23 %) |
||||
| Open | High | Low | Volume | ||
| $1.44 | $1.49 | $1.43 | 9034 | ||
| Last updated 13.08pm 24/05/2024 ? | |||||
| RAC (ASX) Chart |